FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding (2026)

The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, and TB-500 and 7-5 for MOTS-c for inclusion on the 503A Bulk Drug Substances List. Here is what the votes mean, what they do not mean, and the realistic timeline for compounding pharmacy access.

Back to Blog